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Background: Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, is wildly used to treat type 2 diabetes mellitus
(T2DM) with mono- or combination-therapy. We review two previously published open-label studies to extract
insights on the long-term efficacy and safety of vildagliptin.
Methods: Two studies were conducted in Japan to assess the efficacy and safety of vildagliptin as an add-on to
other oral antidiabetes drugs (OADs) for 52 weeks. These studies were performed under the similar protocol in
Japanese patients with T2DM who were inadequately controlled with OAD monotherapy [excluding other
dipeptidyl peptidase-4 (DPP-4) inhibitors].
Results: Addition of vildagliptin (50 mg twice daily) to other OAD monotherapy [sulfonylurea (SU), metformin,
thiazolidinedione, alpha-glucosidase inhibitor and glinide] reduced glycated hemoglobin (HbA1c) levels by −0.
64 %,−0.75 %,−0.92 %,−0.94 % and − 0.64 %, respectively, over 52 weeks of treatment. Overall, the incidence of
hypoglycemia was low and was slightly higher in the add-on to SU treatment group compared with the other
groups. The incidences of adverse events were comparable among the treatment groups, and vildagliptin was
well-tolerated as add-on therapy to other OADs.
Conclusions: The evidence from the two studies indicates that vildagliptin as an add-on therapy to other OADs is
a clinically reasonable option for Japanese patients with T2DM who respond inadequately to other OAD
monotherapy.
Keywords: Combination therapy, Dipeptidyl peptidase-4 inhibitor, Long-term administration, Oral antidiabetes
drugs, VildagliptinBackground
The Japanese guideline [1] and the international
guidelines [2] for management of patients with type 2
diabetes mellitus (T2DM) recommend maintaining
tight glycemic control to suppress aggravation and/or
occurrence of vascular complications, providing that
tight glycemic control can be achieved without
hypoglycemia or other significant adverse effects. The* Correspondence: odawara@tokyo-med.ac.jp
1The Department of Diabetology, Endocrinology, Metabolism and
Rheumatology, Tokyo Medical University, 6-7-1, Nishi-Shinjuku, Shinjuku-ku,
Tokyo 160-0023, Japan
Full list of author information is available at the end of the article
© 2016 Odawara and Sagara. Open Access Th
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zeJapanese Diabetes Society (JDS) recommends glycated
hemoglobin (HbA1c) <7.0 % [National Glycohemoglo-
bin Standardization Program (NGSP)] as a general
glycemic goal for patients with T2DM. However, many pa-
tients in Japan do not achieve this goal [3, 4]. For people
with diabetes who do not achieve glycemic control with
lifestyle changes including diet and exercise, the JDS rec-
ommends treatment with oral antidiabetes drugs (OADs)
that should be selected based on the individual patients’
clinical profile. Furthermore, for patients inadequately
controlled on monotherapy, the guideline recommends
combination therapy with a second drug having a different
mode of action [1].is article is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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hibitor as monotherapy has been used in Japan since
2009, and recently patients are increasingly being
treated with combination of DPP-4 inhibitors and
other OADs [3, 5]. DPP-4 inhibitors maintain the
concentrations of incretins, glucagon-like peptide-1
(GLP-1) and glucose-dependent insulinotropic poly-
peptide, especially during the postprandial period.
Thus, like GLP-1 receptor agonists, DPP-4 inhibitors
reduce fasting and postprandial blood glucose levels
through the effect of incretins on increasing the α-
and β-cell sensitivity to glucose levels [6, 7]. DPP-4
inhibitors are generally weight-neutral and have a low
risk of hypoglycemia. They are not also associated
with the adverse gastrointestinal effects reported with
GLP-1 receptor agonists [8].
Vildagliptin, a DPP-4 inhibitor, was launched in
Japan in 2010. In large global studies with a predom-
inantly Caucasian population, vildagliptin has been
demonstrated to be well tolerated and efficacious, as
monotherapy and in combination with metformin
(Met), sulfonylurea (SU), thiazolidinedione (TZD), or
insulin [9–13]. Some reports suggested that Asian pa-
tients with T2DM have a more prominent insulin
secretory defect than Caucasian patients [14]. Also,
Japanese regulatory requirements [15] mandated that
the indication for combination therapy with other
OADs should be supported with data from the Japa-
nese population; this is to ensure there are no
marked differences in the safety and efficacy profiles
of OADs drugs among different ethnicities. In a pre-
viously published Japanese study, vildagliptin demon-
strated stable improvements in HbA1c levels, with
relatively low hypoglycemic risk, either as monother-
apy or as an add-on to SU for treatment duration of
up to 52 weeks [16]. Interestingly, the blood-glucose
lowering effect appeared to be numerically better in
the Japanese population than in the general global
population, which was largely derived from non-Asian
populations.
The present study reviewed the results of two open-
label studies [16, 17] to provide insights on the long-term
efficacy and safety of vildagliptin in combination with
other OADs in Japanese patients with T2DM with inad-
equate glycemic control on OAD monotherapy. These
studies have been previously published in Japanese.
Methods
Two multicenter, open-label studies were included to
evaluate the long-term tolerability and safety of vilda-
gliptin as an add-on to other OAD. Study A, in
which vildagliptin was added to SU, was completed in
2007 [16], and Study B, in which vildagliptin was
added to other OAD [Met, TZD, glinide, or α-glucosidase inhibitor (α-GI)] was completed in 2012
[17]. Inclusion and exclusion criteria were similar in
both the studies; patients aged ≥20 years, inadequately
controlled [HbA1c (NGSP) ≥6.9 % and ≤10.5 % and
fasting plasma glucose (FPG) <270 mg/dL] with OAD
monotherapy in addition to diet/exercise therapy were
enrolled. The common exclusion criteria of the stud-
ies were as follows; pregnant or lactating women, pa-
tients with a history of type 1DM or secondary DM,
acute metabolic complications within past 24 weeks,
acute infection within past 4 weeks, abnormal value
in clinical testing (aspartate aminotransferase or ala-
nine aminotransferase activities > 2-2.5 times the
upper limit of normal, high level of serum creatinine >
2 mg/dL, or fasting triglyceride > 500–700 mg/dL. After
the patient provided written informed consent, vildagliptin
[50 mg twice daily (bid)] was administered in addition to
OAD for 52 weeks.
For each OAD therapy, changes in HbA1c levels from
baseline to 52 weeks or study endpoint were examined.
Changes from baseline to endpoint in FPG, fasting insu-
lin, fasting lipids, homeostasis model assessments for β-
cell function (HOMA-β) and insulin resistance (HOMA-
IR), and body weight were also evaluated. In addition,
the proportion of responders, defined as achieving
HbA1c <6.9 % at endpoint or a ≥1.0 % and ≥0.5 % re-
duction in HbA1c from baseline to endpoint were calcu-
lated. When parameters were not measured at endpoint,
missing values were imputed using the last observation
carried forward method. No hypothesis testing was per-
formed and the data were summarized descriptively by
treatment. Safety analysis included recording of
treatment-emergent adverse events (AEs) and serious
AEs (SAEs). Both studies were approved by the institu-
tional review board at each institute which participated
in the studies and all the subjects enrolled gave written
informed consent prior to start of administration of the
study drug. Also, the studies were conducted in accord-
ance with the Helsinki declaration and good clinical
practices.Results
Patient characteristics
Baseline characteristics of patients by OAD therapy
group are presented in Table 1. Overall, 299 patients
were enrolled: 54 were on SU, 58 were on Met, 62 were
on TZD, 62 were on α-GI, and 63 were on glinide. The
mean age was ~60 years, and the mean body mass index
(BMI) was ~25 kg/m2. For patients treated with SU
(Study A), the mean baseline HbA1c levels and the mean
duration of T2DM were numerically higher and longer,
respectively, compared with patients in the other OAD
groups. As one patient enrolled in the add-on to SU
Table 1 Patient demographics and baseline characteristics
Study A Study B
Parameters SU Met TZD α-GI Glinide
n = 54 n = 58 n = 62 n = 62 n = 63
Gender, n (%)
Men 39 (72.2) 35 (60.3) 50 (80.6) 42 (67.7) 45 (71.4)
Women 15 (27.8) 23 (39.7) 12 (19.4) 20 (32.3) 18 (28.6)
Age (years) 60.6 ± 10.24 58.0 ± 11.06 59.0 ± 11.24 60.9 ± 10.41 59.9 ± 12.10
BMI (kg/m2) 24.7 ± 3.10 26.0 ± 3.47 26.5 ± 3.77 24.8 ± 3.73 25.0 ± 3.55
Duration of type 2 diabetes mellitus (years) 9.1 ± 6.61 6.8 ± 5.91 6.6 ± 4.90 6.9 ± 5.25 5.7 ± 4.76
HbA1ca (%) 8.0 ± 0.71 7.80 ± 0.87 7.80 ± 0.91 7.66 ± 0.76 7.97 ± 0.89
Fasting plasma glucose (mg/dL) 153.6 ± 28.26 156.1 ± 32.97 155.5 ± 32.16 155.2 ± 28.18 177.7 ± 51.10
GFR (MDRD) category, n (%)
>80 mL/min/1.73 m2 48 (88.9) 52 (89.7) 58 (93.5) 52 (83.9) 53 (84.1)
≤80 mL/min/1.73 m2 6 (11.1) 6 (10.3) 4 (6.5) 10 (16.1) 10 (15.9)
Values are expressed as n (%) or mean ± standard deviation
One of 54 patients enrolled in SU add-on therapy did not receive the study drug (vildagliptin); therefore, 53 patients were analyzed for safety and efficacy
aHbA1c calculated from JDS value to NGSP value: HbA1c (NGSP) (%) = 1.02 × HbA1c (JDS) (%) + 0.25 %
α-GI alpha-glucosidase inhibitor, BMI body mass index, GFR glomerular filtration rate, Met metformin
MDRD modification of diet in renal disease, SU sulfonylurea, TZD thiazolidinedione
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lyzed for safety and efficacy assessments.
HbA1c
As shown in Fig. 1, HbA1c decreased rapidly within the
initial three months after addition of vildagliptin in all
groups, and the time course of change in HbA1c there-
after was similar in all groups. The decrease in HbA1c
after 12 weeks of vildagliptin treatment in each group
ranged between 0.82 % – 1.09 %. At endpoint, HbA1c
reductions in the add-on to SU, Met, TZD, α-GI, and
glinide, groups were 0.64 %, 0.75 %, 0.92 %, 0.94 %, and
0.64 %, respectively.
Responders
The percentage of responders after add-on treatment
with vildagliptin is shown in Table 2. The proportion of
patients achieving HbA1c <6.9 % (≤6.9 % for add-on to
SU) was relatively low in the add-on to SU group
(34.6 %) and the add-on to glinide group (37.9 %), but
was >50 % in the other OAD groups. The proportion of
patients achieving an HbA1c reduction of ≥1.0 % was
also low in the add-on to SU group (26.4 %); whereas
the proportion in other groups, including the add-on to
glinide group was ~40 %.
Body weight
The mean body weight at endpoint was increased
slightly in all the groups, however an increase of more
than 2 kg was observed only in the add-on to TZD
group (Table 3).FPG, Fasting Insulin, HOMA-β, HOMA-IR and Fasting
Lipids
After vildagliptin co-administration, mean FPG de-
creased in all the add-on groups. The baseline FPG level
was higher in the add-on to glinide group than in the
other OAD groups, and the change from baseline to
endpoint was relatively small in the add-on to SU group
(Table 4). Fasting insulin levels increased in the add-on
to SU group and slightly increased or decreased in other
OAD groups. HOMA-β increased in all the OAD
groups, and the change was greatest in the add-on to SU
group. The value change in HOMA-IR increased only in
the add-on to SU group and decreased in all the other
OAD groups.
As shown in Table 5, triglyceride, and total choles-
terol levels decreased from baseline to endpoint in all
OAD groups. Low-density lipoprotein cholesterol
levels increased in the add-on to SU group and de-
creased in the other OAD groups. High-density lipo-
protein cholesterol levels slightly increased in the
add-on to α-GI group and decreased in the other
OAD groups.
Adverse events
The incidence of AEs was comparable among the
OAD groups: 90.6 % in the add-on to SU group,
94.8 % in the add-on to Met group, 83.9 % in the
add-on to TZD group, 85.5 % in the add-on to α-GI
group, and 82.5 % in the add-on to glinide group
(Table 6). The most frequent AE was nasopharyngitis
in all the OAD groups. The majority of AEs were
mild or moderate in severity and no death was
Fig. 1 Time-course change in mean glycated hemoglobin (HbA1c) over 52 weeks in patients with type 2 diabetes mellitus treated with
vildagliptin as add-on to other oral antidiabetes drugs. a: Vildagliptin (Vilda) with sulfonylurea (SU), b: Vilda with metformin (Met), c: Vilda with
thiazolidinedione (TZD), d: Vilda with α-glucosidase inhibitor (α-GI), e: Vilda with glinide, f: ΔHbA1c, change in HbA1c at endpoint; E endpoint.
Data are presented as mean ± standard error
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drug reactions was 47.2 % in the add-on to SU group,
29.3 % in the add-on to Met group, 24.2 % in the
add-on to TZD group, 12.9 % in the add-on to α-GI
group and 15.9 % in the add-on to glinide group. At
least one episode of hypoglycemic symptoms was re-
ported in 2 patients (3.8 %) in the add-on to SU
group and 1 patient (1.7 %) in the add-on to Met
group. The hypoglycemic events were moderate in se-
verity and categorized as grade 1. None of the pa-
tients in the TZD, α-GI, or glinide groups reportedhypoglycemic events. Discontinuation of treatment
due to AEs was overall low, occurred in 4 patients
(7.5 %) in the add-on to SU group, 3 patients (5.2 %)
in the add-on to Met group, 4 patients (6.5 %) in the
add-on to TZD group, 4 patients (6.5 %) in the add-
on to α-GI group, and 6 patients (9.5 %) in the add-
on to glinide group.
Discussion
The efficacy and safety analysis from two long-term 52-
week studies showed that vildagliptin 50 mg bid, in
Table 2 Proportion of responders at endpoint
Study A Study B
SU Met TZD α-GI Glinide
na = 53 na = 58 na = 62 na = 62 na = 63
% (n) % (n) % (n) % (n) % (n)
HbA1c <6.9 % or ≤6.9%b 34.6 53.8 59.3 69.6 37.9
(18/52) (28/52) (32/54) (39/56) (22/58)
≥1.0 % reduction in HbA1c 26.4 46.6 41.9 43.5 38.1
(14/53) (27/58) (26/62) (27/62) (24/63)
≥0.5 % reduction in HbA1c 60.4 69.0 74.2 80.6 61.9
(32/53) (40/58) (46/62) (50/62) (39/63)
aNumber of patients with both baseline and endpoint HbA1c measurements in the specified population, which was used as denominator, unless
specified otherwise
bDenominator consists of patients with baseline HbA1c ≥6.9 % and endpoint HbA1c measurement. In SU group, HbA1c ≤6.9 % was employed as criteria
of responder
α-GI alpha-glucosidase inhibitor, Met metformin, SU sulfonylurea, TZD thiazolidinedione
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T2DM, exerts robust blood glucose-lowering effects and
is well tolerated. There was no remarkable difference in
the incidence of AEs among the OADs used as baseline
therapy. The risk of hypoglycemia was overall low, with
a slight increase in the add-on to SU group. The events
were mild in severity and were manageable by the
patients.
DPP-4 inhibitors are relatively new drugs among
OADs, however, their use in T2DM patients is mark-
edly increasing in the clinical setting. The blood-
glucose lowering effect of DPP-4 inhibitor has been
well recognized, but only few studies to investigate
the differences among DPP-4 inhibitors are available
[18]. An indirect comparison adjusted for the back-
ground characteristics in Japanese patients with
T2DM revealed that the effect of vildagliptin (50 mg
bid) in reducing HbA1c levels was significantly stron-
ger compared to sitagliptin (50 or 100 mg qd) [19].
Concerning the mode of enzyme inhibition by DPP-4
inhibitors, the inhibition kinetics of vildagliptin was
slower than that of sitagliptin [20, 21]. This difference
in the kinetics of DPP-4 inhibition may be related
with the significant suppression of blood glucose fluc-
tuations during 24 h with vildagliptin compared to
sitagliptin [22]. However, HbA1c prior to treatment
with DPP-4 inhibitors is strongly associated with the
variance of HbA1c reduction in response to DPP-4Table 3 Change in body weight
Study A Study B
SU Met
n = 53 n = 58
Baseline (kg) 66.01 ± 1.65 68.76 ± 1.285
Change at endpoint (kg) 1.49 ± 0.26 0.51 ± 0.330
Values are expressed mean ± standard error
α-GI alpha-glucosidase inhibitor, Met metformin, SU sulfonylurea, TZD thiazolidinediinhibitors [23]. The efficacy and safety of vildagliptin
in long-term observation has remained to be eluci-
dated thoroughly.
Addition of vildagliptin 50 mg bid resulted in a rapid
decrease in HbA1c in all the OAD groups. The combin-
ation of vildagliptin and other OADs provided an effect-
ive glucose-lowering therapy, but attention should be
paid to hypoglycemic events as well as refractoriness in
the reduction of HbA1c levels, especially when vildaglip-
tin is administered in combination with insulin secreta-
gogues for an extended period. In the current studies,
the degree of HbA1c reduction by vildagliptin in com-
bination with insulin secretagogues (SU or glinide) was
relatively smaller when compared to the combination
with non-insulin secretagogues (Met, TZD, or α-GI).
In addition to hypoglycemia, weight gain is another
important issue to be considered while choosing
pharmacotherapy for the management of T2DM [24]. In
these studies, a >1 kg increase in weight was found with
the add-on to insulin secretagogues (SU, glinide) and
TZD therapy, in contrast to a previous study on sitaglip-
tin, where weight reduction was observed due to a de-
crease in dose of SU [25]. The increase in body weight
in the add-on to insulin secretagogues group is presum-
ably due to defensive eating secondary to the increased
tendency to mild hypoglycemia in the SU and glinide
groups; in the TZD group it is not clear why the usual
increase in weight is exacerbated by the addition ofTZD α-GI Glinide
n = 62 n = 62 n = 63
72.29 ± 1.749 65.60 ± 1.634 66.81 ± 1.728
2.11 ± 0.318 0.45 ± 0.323 1.17 ± 0.281
one
Table 4 Change in fasting plasma glucose, fasting insulin, HOMA-β and HOMA − IR
Study A Study B
SU Met TZD α-GI Glinide
n = 53 n = 58 n = 62 n = 62 n = 63
Fasting plasma glucose (mg/dL)
Baseline 153.0 ± 3.88 156.1 ± 4.33 155.5 ± 4.08 155.2 ± 3.58 177.7 ± 6.44
Δ change −6.6 ± 3.76 −14.0 ± 3.78 −19.6 ± 2.94 −17.0 ± 3.49 −18.8 ± 4.60
Fasting insulin (μU/L)
Baseline 7.90 ± 0.56 8.33 ± 0.616 6.43 ± 0.536 7.58 ± 0.691 7.13 ± 0.638
Δ change 1.92 ± 0.93 −0.23 ± 0.478 −0.56 ± 0.298 0.02 ± 0.383 −0.04 ± 0.459
HOMA-β
Baseline 33.10 ± 2.41 35.09 ± 3.28 28.13 ± 2.67 32.83 ± 4.08 25.66 ± 2.39
Δ change 11.30 ± 2.89 6.76 ± 3.34 5.79 ± 1.94 4.64 ± 2.06 4.50 ± 1.61
HOMA-IR
Baseline 3.07 ± 0.26 3.31 ± 0.29 2.42 ± 0.20 2.89 ± 0.25 3.26 ± 0.39
Δ change 0.76 ± 0.56 −0.36 ± 0.19 −0.53 ± 0.12 −0.23 ± 0.17 −0.43 ± 0.26
Values are expressed as mean ± standard error
Δ change from baseline to endpoint, α-GI alpha-glucosidase inhibitor, HOMA homeostasis model assessment, Met metformin, SU sulfonylurea,
TZD thiazolidinedione
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gate body weight [26].
One limitation of this manuscript is that two inde-
pendent clinical studies were reviewed in a parallel man-
ner; hence, no statistical analysis was performed to
compare efficacy and safety parameters among the dif-
ferent treatment groups. Another limitation is that only
combination of vildagliptin with OAD was focused in
this article, although it has been reported that vildaglip-
tin as add-on to insulin significantly reduced HbA1c inTable 5 Change in fasting lipids
Study A Study B
SU Met
n = 53 n = 58
Triglyceride (mg/dL)
Baseline 137.9 ± 13.09 158.0 ± 12.48
Δ change −6.6 ± 9.28 −19.4 ± 11.42
Total cholesterol (mg/dL)
Baseline 197.8 ± 3.95 195.0 ± 4.19
Δ change −3.3 ± 3.22 −7.1 ± 2.40
Low-density lipoprotein (mg/dL)
Baseline 123.8 ± 3.81 115.8 ± 3.51
Δ change 1.3 ± 2.77 −0.9 ± 2.44
High-density lipoprotein (mg/dL)
Baseline 51.5 ± 1.45 55.4 ± 1.85
Δ change −1.8 ± 0.74 −1.4 ± 1.03
Values are expressed as mean ± standard error
aMeasurements for one patient in the α-GI group and two patients in the glinide gr
Δ change from baseline to endpoint, α-GI alpha-glucosidase inhibitor, Met metformJapanese patients with T2DM [27]. Concerning the
safety of DPP-4 inhibitors, no studies have revealed that
DPP-4 inhibitors provide beneficial outcome on inci-
dence of cardiovascular events, however, meta-analysis
have shown that DPP-4 inhibitors have a neutral effect
on major cardiovascular events [28, 29].
Conclusions
In conclusion, vildagliptin as an add-on to other
OADs in Japanese patients with T2DM results inTZD α-GI Glinide
n = 62 n = 61a n = 61a
131.6 ± 11.69 150.5 ± 17.80 155.8 ± 13.68
−7.8 ± 7.93 −12.3 ± 12.90 −8.7 ± 10.21
199.0 ± 4.45 200.0 ± 4.47 206.9 ± 4.98
−7.2 ± 3.74 −5.3 ± 3.53 −7.6 ± 3.37
115.3 ± 3.60 122.7 ± 4.22 126.1 ± 4.21
−1.5 ± 3.19 −1.2 ± 3.31 −2.3 ± 3.10
62.5 ± 2.54 54.1 ± 1.58 57.2 ± 1.76
−2.0 ± 1.22 0.4 ± 0.82 −1.1 ± 1.21
oup were missing
in, SU sulfonylurea, TZD thiazolidinedione
Table 6 Adverse events
Study A Study B
n (%) SU Met TZD α − GI Glinide
n = 53 n = 58 n = 62 n = 62 n = 63
Adverse events (AEs) 48 (90.6) 55 (94.8) 52 (83.9) 53 (85.5) 52 (82.5)
Adverse drug reactions 25 (47.2) 17 (29.3) 15 (24.2) 8 (12.9) 10 (15.9)
Serious AEs 3 (5.7) 4 (6.9) 5 (8.1) 4 (6.5) 2 (3.2)
Discontinuation due to AEs 4 (7.5) 3 (5.2) 4 (6.5) 4 (6.5) 6 (9.5)
Patients with at least one episode of hypoglycemic symptoms 2 (3.8) 1 (1.7) 0 (0.0) 0 (0.0) 0 (0.0)
AEs by preferred term >5 %
Nasopharyngitis 25 (47.2) 17 (29.3) 13 (21.0) 25 (40.3) 20 (31.7)
Constipation 4 (7.5) 9 (15.5) 3 (4.8) 4 (6.5) 5 (7.9)
Back pain 8 (15.1) 3 (5.2) 4 (6.5) 5 (8.1) 3 (4.8)
Gastritis 6 (11.3) 5 (8.6) 4 (6.5) 2 (3.2) 1 (1.6)
Upper respiratory tract infection 1 (1.9) 3 (5.2) 4 (6.5) 1 (1.6) 4 (6.3)
Dizziness 5 (9.4) 2 (3.4) 2 (3.2) 2 (3.2) 5 (7.9)
Contusion 1 (1.9) 3 (5.2) 1 (1.6) 1 (1.6) 5 (7.9)
Bronchitis 1 (1.9) 5 (8.6) 0 (0.0) 3 (4.8) 1 (1.6)
Edema peripheral 0 (0.0) 1 (1.7) 4 (6.5) 2 (3.2) 1 (1.6)
Blood amylase increased 3 (5.7) 3 (5.2) 3 (4.8) 2 (3.2) 0 (0.0)
Osteoarthritis 1 (1.9) 3 (5.2) 3 (4.8) 0 (0.0) 2 (3.2)
Headache 1 (1.9) 3 (5.2) 1 (1.6) 1 (1.6) 3 (4.8)
Diarrhea 0 (0.0) 5 (8.6) 1 (1.6) 1 (1.6) 0 (0.0)
Hunger 7 (13.2) 3 (5.2) 1 (1.6) 1 (1.6) 2 (3.2)
Hypoesthesia 1 (1.9) 0 (0.0) 3 (4.8) 0 (0.0) 4 (6.3)
Conjunctivitis allergic 0 (0.0) 4 (6.9) 0 (0.0) 0 (0.0) 2 (3.2)
Periodontitis 0 (0.0) 0 (0.0) 1 (1.6) 4 (6.5) 1 (1.6)
Dry eye 0 (0.0) 0 (0.0) 4 (6.5) 0 (0.0) 1 (1.6)
C-reactive protein increased 2 (3.8) 4 (6.9) 0 (0.0) 0 (0.0) 1 (1.6)
Arthralgia 3 (5.7) 3 (5.2) 1 (1.6) 0 (0.0) 1 (1.6)
Pharyngitis 1 (1.9) 10 (17.2) 3 (4.8) 1 (1.6) 1 (1.6)
Blood creatine phosphokinase increased 7 (13.2) 2 (3.4) 2 (3.2) 1 (1.6) 1 (1.6)
Tremor 7 (13.2) 1 (1.7) 1 (1.6) 0 (0.0) 0 (0.0)
Asthenia 6 (11.3) 2 (3.4) 0 (0.0) 2 (3.2) 2 (3.2)
Blood creatine phosphokinase MB increased 5 (9.4) 2 (3.4) 1 (1.6) 1 (1.6) 0 (0.0)
Hyperhidrosis 4 (7.5) 2 (3.4) 0 (0.0) 0 (0.0) 2 (3.2)
Hypertension 3 (5.7) 2 (3.4) 2 (3.2) 2 (3.2) 2 (3.2)
Eczema 3 (5.7) 2 (3.4) 2 (3.2) 2 (3.2) 2 (3.2)
Myalgia 3 (5.7) 1 (1.7) 1 (1.6) 0 (0.0) 1 (1.6)
Palpitations 3 (5.7) 1 (1.7) 1 (1.6) 3 (4.8) 1 (1.6)
Anemia 3 (5.7) 1 (1.7) 0 (0.0) 2 (3.2) 0 (0.0)
α-GI alpha-glucosidase inhibitor, Met metformin, SU sulfonylurea, TZD thiazolidinedione
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ity and low risk of hypoglycemia and weight gain.
Vildagliptin improved glucose metabolism regardless
of the type of OADs combined with vildagliptin.Vildagliptin is considered to be a clinically reason-
able treatment option with good tolerability profile
for patients with T2DM responding inadequately to
other OADs.
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